JIALIN WU^1,2,#, ZEHONG CHEN³, WENWEI LIU^1,#, YONGXIN ZHANG¹, WEI FENG¹, YUJIE YUAN¹, JINNING YE¹, LIANG WANG¹, SHIRONG CAI¹, YULONG HE¹, SUIJING WU^4,*, WU SONG^1,*

Oncology Research, Vol.29, No.2, pp. 119-128, 2021, DOI:10.32604/or.2022.03178

Abstract Objective: MicroRNA-188-5p (miR-188) enhances oncologic progression in various human malignancies. This study aimed to explore its role in colorectal cancer (CRC). Materials and Methods: Human CRC tissues paired with normal tissues, and several CRC cell lines were utilized. Real-time quantitative PCR was applied to measure the expression of miR-188. Overexpression and knockdown were used to access the function of miR-188 and to investigate whether FOXL1/Wnt signaling mediates such function. The proliferation, migration and invasion of cancer cells were evaluated by CCK8, wound-healing and transwell assays, respectively. Whether FOXL1 acted as a direct target of miR-188 was verified by dual-luciferase reporter… More >

YUHUA ZOU^1,#, LEI ZHANG^2,#, XIN ZHONG^3,*

BIOCELL, Vol.46, No.5, pp. 1309-1317, 2022, DOI:10.32604/biocell.2022.018167

Abstract Renal cell carcinoma (RCC) has a poor prognosis due to limited diagnosis and treatment. Thus, it is necessary to find novel prognostic biomarkers and therapeutic targets. The aberrant expression of microRNAs plays an important role in RCC oncogenesis. Tissue inhibitors of metalloproteinase 3 (TIMP3) acts as a downstream target of miR-181b. The aim of this study was to understand the role and molecular mechanism of miR-181b in RCC oncogenesis. The results showed that miR-181b expression was significantly higher in RCC tumour tissues, especially in those with significant invasion or metastasis. miR-181b overexpression promoted proliferation and migration of the RCC cell… More >

Pierre-Guillaume Poureau^1,2,*, Jean-Philippe Metges²

Oncologie, Vol.23, No.1, pp. 47-59, 2021, DOI: 10.32604/Oncologie.2021.15525

Abstract Immunotherapy for digestive cancers is booming and for the first time an immune checkpoint inhibitor has been granted marketing authorization for the treatment of digestive cancer. In order to better understand the mecanism of action of these treatments, their adverse events and the escape mecansim, it is necessary to know the fundamentals of cancer immunology. The innate and adaptive immune system allows the elimination of cancer cells by direct non-specific cytotoxicity (Natural Killer cells), by the development of an adaptive cell-mediated response (dendritic cells becoming antigen presenting cells, allowing the differentiation of lymphocytes naive in CD4 and CD8 T lymphocytes)… More >